I 
117TH CONGRESS 
1ST SESSION 
H. R. 467 
To amend the Families First Coronavirus Response Act and the CARES 
Act to require group health plans and health insurance issuers offering 
group or individual health insurance coverage to provide coverage, with-
out cost sharing, of certain COVID–19 antibody treatments. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 25, 2021 
Mr. GONZALEZ of Ohio (for himself and Ms. SPANBERGER) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committees on Ways and Means, and Edu-
cation and Labor, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To amend the Families First Coronavirus Response Act and 
the CARES Act to require group health plans and health 
insurance issuers offering group or individual health in-
surance coverage to provide coverage, without cost shar-
ing, of certain COVID–19 antibody treatments. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Protecting Patient Ac-
cess to Lifesaving COVID–19 Drugs Act of 2021’’. 
VerDate Sep 11 2014 
16:10 Feb 13, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H467.IH
H467
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. REQUIRING GROUP HEALTH PLANS AND HEALTH 
INSURANCE ISSUERS OFFERING GROUP OR 
INDIVIDUAL HEALTH INSURANCE COVERAGE 
TO PROVIDE COVERAGE, WITHOUT COST 
SHARING, OF CERTAIN COVID–19 ANTIBODY 
TREATMENTS. 
(a) IN GENERAL.—Section 6001(a) of the Families 
First Coronavirus Response Act (42 U.S.C. 1320b–5 note) 
is amended— 
(1) in the matter preceding paragraph (1), by 
inserting ‘‘(or, in the case of items and services de-
scribed in paragraph (3), beginning on or after the 
date of the enactment of the Protecting Patient Ac-
cess to Lifesaving COVID–19 Drugs Act of 2021)’’ 
after ‘‘this Act’’; and 
(2) by adding at the end the following new 
paragraph: 
‘‘(3) Items consisting of monoclonal antibody 
infusions (as specified by the Secretary) approved, 
cleared, or otherwise authorized by the Food and 
Drug Administration needed for the treatment of 
COVID–19 in individuals with positive COVID–19 
test results, including services for the administration 
of such items.’’. 
VerDate Sep 11 2014 
16:10 Feb 13, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H467.IH
H467
pamtmann on DSKBC07HB2PROD with BILLS
(b) REIMBURSEMENT
FOR TREATMENTS.—Section 
3202 of the CARES Act (42 U.S.C. 256b note) is amend-
ed— 
(1) in the header, by inserting ‘‘AND ANTI-
BODY TREATMENTS’’ after ‘‘TESTING’’; 
(2) in subsection (a), in the matter preceding 
paragraph (1), by inserting ‘‘or antibody treatment, 
as applicable,’’ after ‘‘diagnostic testing’’; and 
(3) in subsection (b)— 
(A) in the header, by inserting ‘‘AND ANTI-
BODY TREATMENTS’’ after ‘‘TESTING’’; and 
(B) in paragraph (1)— 
(i) by inserting ‘‘or antibody treat-
ment’’ after ‘‘diagnostic test’’; and 
(ii) by inserting ‘‘or treatment (in-
cluding the administration of such treat-
ment)’’ after ‘‘such test’’. 
Æ 
VerDate Sep 11 2014 
16:10 Feb 13, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H467.IH
H467
pamtmann on DSKBC07HB2PROD with BILLS